Cell And Gene Therapy Market Size, Share, Growth and Forecast to 2035

Cell and Gene Therapy Market Size

The Cell and Gene Therapy Market reached US$ 16.89 Billion in 2025 and, based on the stated growth trajectory. The market is expected to reach US$ 156.23 Billion by 2035, growing at a CAGR of 21.5% during the forecast period 2026 to 2033 by expanding approvals, deeper late-stage clinical pipelines, manufacturing scale-up, and increasing commercialization of advanced therapies across oncology, rare diseases, hematology, ophthalmology, and immunology.

Cell and gene therapies are shifting the healthcare industry from chronic disease management toward potentially curative, one-time or durable treatments. Cell therapy involves the administration of living cells to restore, replace, repair, or enhance biological function. Gene therapy introduces, modifies, replaces, or silences genetic material to treat disease at the molecular level. These approaches increasingly overlap in gene-modified cell therapies, where patient-derived or donor-derived cells are genetically engineered before being administered as a therapeutic product. CAR-T cell therapy remains the most commercially visible example, with T cells modified to identify and destroy cancer cells.

The market is now moving into a more complex phase. Growth is no longer driven only by scientific innovation or product approvals. The next competitive cycle will be shaped by therapy pipeline value, gene therapy manufacturing capacity, viral vector bottlenecks, CDMO availability, payer willingness to fund high-cost therapies, country-level regulatory pathways, and the ability of companies to industrialize highly customized products. This creates a strong commercial investigation landscape for investors, pharmaceutical companies, CDMOs, hospital networks, payers, and policy stakeholders.

Key Takeaways

• The cell and gene therapy market reached US$ 16.89 Billion in 2025 and is projected to increase to US$ 156.23 Billion by 2035, reflecting a CAGR of 21.5% during 2026 to 2035.

• The cell and gene therapy market size 2026 is estimated at US$ 20.52 Billion, indicating rapid near-term expansion as approved products move into broader commercial use and late-stage pipelines advance toward regulatory submission.

• Cell therapy is expected to remain the leading therapy type with 61.2% market share, supported by CAR-T adoption, stem cell-based therapies, regenerative medicine platforms, and rising investment in allogeneic cell therapy models.

• North America is expected to dominate the market with 43.7% share, driven by the U.S. regulatory ecosystem, high clinical trial density, advanced treatment centers, strong biotechnology funding, and early adoption of premium advanced therapies.

• The strongest strategic opportunities are emerging in cell therapy pipeline analysis, gene therapy manufacturing capacity, CDMO opportunity in cell and gene therapy, viral vector supply, automated production platforms, and CGT pricing and reimbursement trends.

Cell and Gene Therapy Market Scope

Executive Summary

The cell and gene therapy market is entering a decisive commercialization phase. Early adoption was led by oncology-focused CAR-T therapies and rare disease gene therapies. The next phase will be broader, with pipelines expanding into autoimmune disorders, neurological diseases, inherited blood disorders, ophthalmology, musculoskeletal conditions, and regenerative medicine.

A strong global pipeline is one of the most important indicators of future market value. Current industry datasets show thousands of gene, cell, and RNA therapies in development, with gene therapies and genetically modified cell therapies representing the largest share of active programs. This pipeline depth supports long-term revenue growth, but it also increases pressure on manufacturing infrastructure, viral vector supply, quality control systems, cold-chain logistics, and treatment-center readiness.

The market’s biggest commercial opportunity is therefore not limited to therapy developers. CDMOs, viral vector manufacturers, plasmid DNA suppliers, automated cell processing platform providers, cryopreservation companies, analytical testing providers, and treatment logistics partners are becoming critical value-chain participants. The CDMO opportunity in cell and gene therapy is particularly strong as small and mid-sized biotech companies often lack the capital, technical workforce, and GMP infrastructure required to manufacture advanced therapies at clinical and commercial scale.

At the same time, CGT pricing and reimbursement trends remain a major restraint. One-time gene therapies and personalized cell therapies can carry prices ranging from hundreds of thousands to more than two million dollars per patient. These prices reflect complex manufacturing, small patient populations, clinical value, and potentially long-term disease modification. However, they also create payer uncertainty, budget pressure, and market access delays. As a result, outcomes-based contracts, installment payment models, risk-sharing agreements, annuity-style reimbursement, and national access programs are becoming central to commercialization strategy.

Market Dynamics: Drivers and Restraints

Growing Therapy Pipeline Value is Strengthening Long-Term Market Demand

The most important growth driver for the cell and gene therapy market is the rapid expansion and maturation of the global clinical pipeline. Oncology remains the strongest commercial segment, particularly across hematologic malignancies such as lymphoma, leukemia, and multiple myeloma. However, pipeline activity is expanding into rare inherited disorders, genetic blood diseases, retinal disorders, neurological conditions, autoimmune disease, cardiovascular repair, and tissue regeneration.

A detailed cell therapy pipeline analysis shows that CAR-T therapies continue to dominate genetically modified cell therapy development, while CAR-NK, TCR-T, tumor-infiltrating lymphocyte therapies, stem cell therapies, and allogeneic platforms are gaining momentum. Autologous therapies remain clinically important because of their patient-specific design and strong efficacy in selected indications. However, allogeneic therapies are receiving greater strategic attention because they can potentially reduce manufacturing time, improve scalability, and create off-the-shelf treatment models.

The gene therapy pipeline is similarly evolving. Adeno-associated virus-based therapies continue to lead in several rare disease and ophthalmology programs, while lentiviral vectors remain important in ex vivo gene-modified cell therapies. Non-viral delivery systems, lipid nanoparticles, gene editing platforms, base editing, prime editing, and RNA-guided approaches are increasingly being evaluated as next-generation technologies. This shift is strategically important because it may reduce dependence on some viral vector systems and improve tissue targeting, payload flexibility, and repeat dosing potential.

Rising Approvals are Improving Clinical Confidence and Commercial Adoption

Regulatory approvals across the United States, Europe, China, Japan, and other advanced healthcare markets are improving confidence in the therapeutic and commercial viability of cell and gene therapies. FDA-approved therapies now include CAR-T products, gene therapies for inherited disorders, gene-modified autologous cell therapies, cord blood products, tissue-engineered products, and regenerative medicine products. Products such as Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, Casgevy, Lyfgenia, Zolgensma, Luxturna, Hemgenix, Roctavian, Elevidys, Vyjuvek, Lenmeldy, and others demonstrate how the market has expanded beyond early proof-of-concept.

Approvals are also changing company strategy. Large pharmaceutical companies are using approvals to build franchise depth in oncology, hematology, rare disease, and immunology. Emerging biotech companies are using clinical milestones to secure partnerships, licensing deals, and acquisition interest. Meanwhile, CDMOs and technology suppliers are aligning capacity around the most commercially active modalities, including CAR-T, AAV gene therapy, lentiviral vector-based cell therapy, and gene editing-enabled therapies.

Advanced Delivery Vectors and Non-Viral Platforms are Accelerating Innovation

The growing utilization of advanced delivery vectors is significantly driving market growth. Gene and cell therapies depend on the efficient delivery of genetic material into target cells. Viral vectors such as AAV, lentivirus, retrovirus, and adenovirus have supported many of the earliest successful therapies, but each has technical limitations related to payload capacity, immunogenicity, scalability, tissue targeting, and manufacturing yield.

The industry is now investing heavily in improved capsids, tissue-specific promoters, engineered viral vectors, self-inactivating lentiviral systems, transient transfection improvements, stable producer cell lines, and non-viral technologies. Lipid nanoparticles, polymeric nanoparticles, electroporation, transposon systems, and exosome-based delivery platforms are gaining attention as developers seek safer, more scalable, and more flexible delivery systems.

This delivery innovation is particularly important for in vivo gene therapy, where the therapeutic payload is administered directly into the patient. Better delivery systems could expand the addressable disease pool, reduce dosage requirements, minimize immune responses, and improve long-term efficacy.

Gene Therapy Manufacturing Capacity is Becoming a Strategic Differentiator

Gene therapy manufacturing capacity is now one of the most important competitive variables in the market. Advanced therapies require specialized GMP facilities, validated cleanrooms, highly trained technical teams, complex biological raw materials, aseptic processing, batch-level traceability, advanced analytics, and rigorous release testing.

Autologous cell therapies create additional complexity because each patient can represent a separate manufacturing batch. The process often includes cell collection, shipping to a manufacturing site, activation, genetic modification, expansion, quality testing, cryopreservation, return shipment, lymphodepletion, and reinfusion. Any delay or failure in this chain can affect patient access and commercial performance.

For gene therapies, large-scale vector production is especially challenging. AAV manufacturing requires control over full and empty capsid ratios, potency, purity, yield, scalability, and comparability between clinical and commercial batches. Lentiviral vector manufacturing faces challenges related to stable supply, production cost, quality consistency, and limited global capacity.

Companies with reliable internal manufacturing networks or strong CDMO partnerships are better positioned to scale commercial launches. This is why leading players are investing in manufacturing automation, regional production hubs, digital batch tracking, closed-system processing, decentralized manufacturing concepts, and long-term CDMO capacity reservations.

Viral Vector Bottlenecks Continue to Restrain Market Expansion

Viral vector bottlenecks remain one of the most persistent restraints in the cell and gene therapy market. Demand for AAV, lentiviral, and other viral vector systems has increased faster than the industry’s ability to provide consistent, high-quality, cost-effective supply. This imbalance affects both clinical-stage programs and commercial therapies.

The most common bottlenecks include limited GMP-grade vector capacity, high production costs, long lead times, low yields, batch failures, shortage of experienced manufacturing talent, plasmid DNA supply constraints, analytical testing delays, and difficulty scaling processes from small clinical batches to commercial volumes. These bottlenecks can delay trials, increase development budgets, restrict patient enrollment, and weaken launch readiness.

Viral vector limitations also influence strategic decisions. Some companies are redesigning programs around lower vector doses, improved capsids, producer cell lines, or non-viral delivery. Others are forming partnerships with CDMOs or building internal manufacturing assets to reduce external dependency. For investors and strategic buyers, manufacturing control is increasingly being viewed as a core asset rather than a back-end operational function.

CDMO Opportunity in Cell and Gene Therapy is Expanding Rapidly

The CDMO opportunity in cell and gene therapy is expanding because many therapy developers do not have the infrastructure required to manage advanced therapy production from early clinical development to commercial launch. Small biotech companies often need support with process development, vector manufacturing, cell processing, analytical methods, tech transfer, regulatory documentation, comparability studies, and commercial readiness.

CDMOs are moving from transactional manufacturing providers to strategic development partners. The strongest CDMO models are those that offer integrated services across plasmid DNA, viral vectors, cell processing, fill-finish, quality control, release testing, cryostorage, logistics, and regulatory support. CDMOs that can shorten development timelines, reduce batch variability, automate workflows, and reserve flexible capacity will be especially well positioned.

The landscape is also shifting toward specialization. Some CDMOs focus on AAV and lentiviral vectors, while others specialize in autologous or allogeneic cell therapy, induced pluripotent stem cell-derived products, gene editing workflows, or decentralized manufacturing platforms. This creates opportunities for both large global CDMOs and niche technology-driven service providers.

High Development Cost and Expensive Manufacturing Processes Continue to Restrain Growth

High development costs and expensive manufacturing processes are expected to remain major restraints for the cell and gene therapy market. These therapies require long development timelines, highly specialized scientific talent, complex regulatory submissions, and intensive manufacturing validation. Unlike conventional small molecules, many CGT products cannot rely on standardized, high-volume manufacturing models.

Autologous therapies are especially expensive because they are patient-specific. Manufacturing cost can rise sharply due to individualized batch handling, chain-of-identity requirements, low batch sizes, quality testing, and logistics. Gene therapies face high costs due to viral vector production, specialized raw materials, process optimization, and limited supplier bases.

Therapy pricing reflects these complexities. Some commercial gene therapies have launched at prices exceeding US$ 2 million per patient, while CAR-T therapies commonly require substantial total treatment costs when hospitalization, monitoring, adverse event management, and supportive care are included. These costs can slow adoption, particularly in healthcare systems with budget constraints or fragmented reimbursement frameworks.

CGT Pricing and Reimbursement Trends are Reshaping Market Access

CGT pricing and reimbursement trends are becoming central to market development. Payers recognize the clinical value of durable or potentially curative therapies, but they also face uncertainty around long-term outcomes, patient eligibility, real-world durability, and budget impact. A one-time therapy may be cost-effective over a patient’s lifetime, but the upfront payment can create immediate pressure for insurers, national health systems, and hospital budgets.

As a result, market access strategies are evolving. Outcomes-based contracts are being used to link payment to clinical performance. Installment models are being discussed or piloted to spread costs over several years. Risk-sharing agreements can reduce payer exposure when durability data are still emerging. National access schemes and specialist reimbursement pathways are becoming more important in Europe and other publicly funded healthcare systems.

For companies, reimbursement planning must now begin earlier in clinical development. Payers increasingly expect evidence on durability, quality-adjusted life years, hospitalization reduction, caregiver burden, productivity gains, and long-term healthcare cost offsets. Companies that can build strong health economics evidence alongside clinical efficacy are likely to achieve faster access and stronger adoption.

Market Segment Analysis

The global cell and gene therapy market is segmented by therapy type, application, delivery approach, manufacturing model, end user, and region.

Cell Therapy Segment

The cell therapy segment is expected to hold 61.2% of the market share in the cell and gene therapy market. The segment is supported by strong adoption of CAR-T therapies in hematological malignancies, ongoing development of allogeneic cell therapies, expansion of stem cell-based treatments, and rising clinical activity in regenerative medicine.

Cell therapies have gained commercial traction because they can deliver targeted biological activity in diseases where conventional drugs have limited effect. CAR-T therapies have established strong clinical value in selected blood cancers, while tumor-infiltrating lymphocyte therapies, CAR-NK therapies, TCR-T therapies, and stem cell platforms are expanding the therapeutic base.

The most important strategic shift in this segment is the move from highly individualized autologous models toward scalable allogeneic platforms and automated production systems. If allogeneic therapies demonstrate consistent efficacy and safety, they could materially improve manufacturing economics and patient access.

Gene Therapy Segment

The gene therapy segment is expected to record strong growth through 2035 due to rising approvals for rare genetic diseases, expanding applications in hematology and ophthalmology, and increased investment in gene editing technologies. Gene therapies are particularly attractive because they can potentially address the root cause of monogenic disorders through long-lasting or one-time treatment.

AAV-based therapies remain central to in vivo gene therapy, while lentiviral approaches are widely used in ex vivo modification of hematopoietic stem cells and immune cells. Gene editing-based therapies are expected to create the next wave of growth as developers move beyond gene addition toward precise correction, disruption, or regulation of disease-causing genes.

However, this segment is highly dependent on manufacturing capacity, regulatory confidence, long-term follow-up data, and payer acceptance of high upfront prices.

Application Insights

Oncology

Oncology remains the leading application area for cell and gene therapies. CAR-T therapies have transformed treatment options in several hematological cancers, and the next growth wave is expected to come from earlier-line treatment, multiple myeloma, acute leukemias, solid tumor programs, next-generation CAR constructs, dual-targeting approaches, and combination strategies.

Despite strong progress in blood cancers, solid tumors remain more challenging due to tumor heterogeneity, antigen escape, immunosuppressive microenvironments, and trafficking barriers. Companies that solve these challenges could unlock a major new revenue pool.

Rare Diseases

Rare diseases represent one of the most attractive growth segments for gene therapy. Many rare disorders are caused by single-gene defects, making them suitable for targeted genetic intervention. The commercial model is supported by orphan drug incentives, high unmet need, premium pricing potential, and strong patient advocacy.

However, small patient populations require precise diagnosis, newborn screening, specialist referral networks, and coordinated reimbursement systems. Commercial success depends not only on approval but also on patient identification and treatment-center activation.

Blood Disorders

Blood disorders are becoming a major growth area due to progress in gene-modified hematopoietic stem cell therapies and gene editing approaches. Sickle cell disease, beta-thalassemia, hemophilia, and inherited immune disorders are key areas of development. These indications offer large clinical value because successful therapies can reduce transfusion dependence, painful crises, bleeding episodes, hospitalization, and long-term organ damage.

Regional Analysis

North America

North America is expected to dominate the cell and gene therapy market with 43.7% market share. The region benefits from a mature biotechnology ecosystem, strong venture capital funding, leading academic medical centers, experienced clinical trial networks, high adoption of innovative therapies, and supportive regulatory mechanisms.

The United States remains the most important commercial market due to FDA approval momentum, RMAT designation pathways, orphan drug incentives, strong hospital infrastructure, and the presence of cell and gene therapy top companies. However, reimbursement complexity remains a barrier. Even after approval, patient access can depend on payer policies, treatment-center availability, prior authorization, and real-world evidence requirements.

Europe

Europe is a major market for advanced therapy medicinal products, supported by centralized EMA review, national HTA processes, strong academic research networks, and public healthcare systems. The EMA’s ATMP framework provides a structured pathway for gene therapies, somatic cell therapies, and tissue-engineered products. However, market access can vary significantly by country because reimbursement decisions are handled nationally.

Germany, France, Italy, Spain, and the United Kingdom are important European markets. Germany offers early access advantages but requires robust benefit assessment. France emphasizes health technology evaluation and negotiated pricing. The United Kingdom has demonstrated willingness to support selected CAR-T therapies through NICE and NHS access pathways, but cost-effectiveness evidence remains central.

Asia-Pacific

Asia-Pacific is expected to be the fastest-growing regional market through 2035. China, Japan, South Korea, India, Singapore, and Australia are increasing investments in cell therapy, gene therapy, regenerative medicine, and advanced biologics manufacturing.

China has become a major center for CAR-T development and clinical trial activity, supported by a large patient pool and growing domestic biotech innovation. Japan has a distinctive regenerative medicine framework, including conditional and time-limited approval mechanisms for regenerative medical products. South Korea is advancing cell therapy and regenerative medicine capabilities with growing domestic company participation. India is an emerging opportunity due to its cost-efficient manufacturing base, expanding biotech infrastructure, and rising interest in affordable cell therapy models.

Country-Level Regulatory Pathways

Country-level regulatory pathways are becoming a major factor in market strategy. In the United States, the FDA’s RMAT designation supports therapies intended to treat, modify, reverse, or cure serious conditions when preliminary clinical evidence indicates potential to address unmet medical needs. This pathway can help sponsors engage earlier with regulators and potentially accelerate development.

In Europe, cell and gene therapies are regulated as ATMPs through EMA’s centralized framework, with involvement from the Committee for Advanced Therapies and other scientific committees. Developers must address quality, safety, efficacy, pharmacovigilance, and post-authorization requirements.

Japan offers an important regenerative medicine pathway through its conditional and time-limited approval framework, enabling earlier market entry for selected regenerative products when safety is confirmed and efficacy is reasonably expected. This makes Japan strategically important for regenerative medicine developers.

In the United Kingdom, NICE and NHS England play a decisive role in access. Reimbursement decisions depend heavily on clinical benefit, cost-effectiveness, eligible population size, and evidence maturity. This makes the UK a key market for studying advanced therapy pricing and access models.

Competitive Landscape

The cell and gene therapy top companies include Novartis AG, Gilead Sciences through Kite Pharma, Bristol Myers Squibb, Johnson & Johnson through Janssen, Vertex Pharmaceuticals, CRISPR Therapeutics, Sarepta Therapeutics, CSL Behring, Amgen, Orchard Therapeutics, Krystal Biotech, bluebird bio, PTC Therapeutics, BioMarin Pharmaceutical, Ferring Pharmaceuticals, Iovance Biotherapeutics, Autolus, Regeneron, Mesoblast, and Abeona Therapeutics.

Emerging and pipeline-focused companies include Editas Medicine, Intellia Therapeutics, Rocket Pharmaceuticals, Regenxbio, Affinia Therapeutics, Beam Therapeutics, Precision BioSciences, Cellectis, Allogene Therapeutics, Caribou Biosciences, Poseida Therapeutics, 2seventy bio, Legend Biotech, and other gene editing, CAR-T, CAR-NK, and vector technology developers.

Competition is increasingly shaped by four capabilities: differentiated clinical efficacy, manufacturing reliability, payer evidence, and lifecycle expansion. Companies with approved products are working to expand indications, improve manufacturing turnaround time, increase treatment-center capacity, and build real-world evidence. Pipeline companies are focusing on next-generation platforms, allogeneic approaches, non-viral delivery, and lower-cost production models.

Company Strategy Analysis

Novartis remains a key player through its established presence in CAR-T and gene therapy, including Kymriah and Zolgensma-related capabilities. Its strategy is centered on high-value advanced therapies, manufacturing resilience, and pipeline selectivity.

Gilead Sciences, through Kite Pharma, is one of the strongest commercial players in CAR-T therapy. Kite’s strategy focuses on blood cancer leadership, manufacturing optimization, global treatment access, and pipeline expansion through internal development and partnerships.

Bristol Myers Squibb has built a strong cell therapy portfolio through products such as Abecma and Breyanzi. Its strategy emphasizes scalable cell therapy operations, broader manufacturing networks, and next-generation cell therapy development.

Vertex Pharmaceuticals has become a major gene editing commercialization player through Casgevy, developed with CRISPR Therapeutics. Its strategy highlights the importance of authorized treatment centers, specialized administration networks, and long-term outcomes data.

Sarepta Therapeutics, CSL Behring, BioMarin, Krystal Biotech, Orchard Therapeutics, bluebird bio, and PTC Therapeutics are important gene therapy players with strong relevance in rare diseases, neuromuscular disorders, hematology, ophthalmology, and inherited conditions.

Recent Developments

• In 2026, the market continued to show strong regulatory and commercial momentum, with approved product lists expanding and more companies prioritizing manufacturing efficiency, evidence generation, and treatment access.

• In 2025, the global gene, cell, and RNA therapy pipeline showed signs of selectivity, with companies reducing some early preclinical exposure while maintaining strong commitment to clinical-stage programs. This indicates a more disciplined development environment rather than weakening long-term demand.

• In 2025, reimbursement decisions for next-generation CAR-T therapies in the United Kingdom highlighted the growing importance of national access pathways, health technology assessment, and real-world value evidence for commercial adoption.

• In 2025 and 2026, viral vector manufacturing remained a key bottleneck, increasing demand for specialized CDMOs, improved production systems, and better analytical platforms.

• leading pharmaceutical companies have expanded cell therapy manufacturing networks, entered long-term capacity agreements, and invested in automation to reduce turnaround time and increase commercial readiness.

The global cell and gene therapy market report delivers a detailed analysis with 54 key tables, more than 46 visually impactful figures, and 187 pages of expert insights, providing a complete view of the market landscape.